Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOX1 | Q06278 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8065724 | 0.97 | LMNA (0.44) | AOX1ACHENPSR1LMNA | |
| SCHEMBL29774222 | 0.91 | BCHE (0.44) | ACHENPSR1LMNA | |
| SCHEMBL10126572 | 0.83 | USP2 (0.46) | LMNA | |
| SCHEMBL16376908 | 0.80 | BCHE (0.42) | ACHENPSR1LMNA | |
| SCHEMBL9417718 | 0.79 | TSHR (0.45) | ACHELMNA | |
| SCHEMBL8658558 | 0.78 | CETP (0.45) | — | |
| SCHEMBL5248630 | 0.78 | CETP (0.47) | AOX1ACHENPSR1 | |
| SCHEMBL31609290 | 0.77 | NPSR1 (0.43) | AOX1ACHENPSR1 | |
| SCHEMBL7331812 | 0.77 | CETP (0.47) | — | |
| SCHEMBL2570674 | 0.76 | LMNA (0.43) | ACHELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080124273-A1 | Novel cationic metal complex radiopharmaceuticals | PURDUE RESEARCH FOUNDATION | 2008-05-29 | — | — | US | disclosed |
| WO-2006080993-A1 | NOVEL CATIONIC METAL COMPLEX RADIOPHARMACEUTICALS | PURDUE RESEARCH FOUNDATION (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080124273-A1 | Novel cationic metal complex radiopharmaceuticals | SLC39A14, CLTC, TMEM165 | AOX1 4845/4885ACHE 2931/4885NPSR1 4314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.